12th week of 2015 patent applcation highlights part 55 |
Patent application number | Title | Published |
20150080274 | Low-Density Composite Propping Agents - Composite propping agents of low density and of high mechanical strength are based on a thermoplastic polymer matrix, in particular having low compressive deformation at high temperatures are especially useful in the field of well fracturing for the recovery of sludges, liquids and gases present in underground reservoirs, and in particular in the field of the extraction of hydrocarbons, such as crude oil or natural gas. | 2015-03-19 |
20150080275 | Process For Inhibition Of Sulphide Scales - The invention provides for the use of a copolymer, comprising
| 2015-03-19 |
20150080276 | PHOSPHORIC ESTER PREPARATIONS WITH REDUCED HYGROSCOPICITY - The present invention relates to phosphoric ester preparations with reduced hygroscopicity, to use of these as flame retardants and hydraulic fluids, and to polyurethanes which comprise the phosphoric ester preparations of the invention. | 2015-03-19 |
20150080277 | LUBRICATING OIL COMPOSITION, AND SLIDING MECHANISM USING LUBRICATING OIL COMPOSITION - Disclosed is a lubricating oil composition for low-friction sliding materials, which is used in a sliding mechanism where a DLC film containing hydrogen in an amount of from 5 atom % to 50 atom % is formed on at least one sliding surface. The lubricating oil composition contains, in the lubricant base oil therein and based on the total amount of the composition, (A) an organic zinc dithiophosphate in an amount of from 0.005% by mass to 0.12% by mass in terms of the phosphorus concentration therein, (B) an amine-based friction-reducing agent in an amount of from 0.05% by mass to 5.0% by mass, and (C) an alkaline earth metal salicylate-based detergent and/or an alkaline earth metal sulfonate-based detergent in an amount of from 0.05% by mass to 0.5% by mass in terms of the alkaline earth metal concentration therein, wherein the component (A) contains, based on the total amount of the composition, a zinc primary dialkyldithiophosphate in an amount of from 0.005% by mass to 0.05% by mass in terms of the phosphorus concentration therein. | 2015-03-19 |
20150080278 | LUBRICATING OIL ADDITIVE COMPOSITION AND LUBRICATING OIL COMPOSITION - A lubricating oil additive composition contains a borated succinimide derivative and an amino alcohol compound. A lubricating oil composition containing the lubricating oil additive composition is excellent in high-temperature detergency and base value retention (long-drain capabilities) even though a blended content of a metal detergent is low and an ash content is small. | 2015-03-19 |
20150080279 | Electrorheological Compositions - The present invention relates to an electrorheological composition with corrosion-inhibiting properties, methods for the production thereof and the use thereof. | 2015-03-19 |
20150080280 | LUBRICATING OIL COMPOSITION - A lubricating oil composition comprising (A) an ethylene/α-olefin copolymer satisfying all of the following requirements (A-1) to (A-3) : (A-1) an ethylene structural unit content of 30 to 70% by mol, (A-2) a kinematic viscosity at 100° C. of 20 to 3000 mm | 2015-03-19 |
20150080281 | MANUFACTURING PROCESS FOR AN ANTI-LIME SCALE PRODUCT - This invention concerns the process for the manufacture of an “anti-lime scaling” product, that is, a product designed to inhibit the formation of lime scale in elements such as pipes or hoses that could be subject to deterioration over time due to lime scale deposits. Specifically, the process of the invention is for an ecological anti-lime scale product. For this, the process according to the invention comprises a preparation step ( | 2015-03-19 |
20150080282 | CLEANSING AND FILM-FORMING WASHES FOR TURBINE COMPRESSORS - Cleansing washes for compressor sections of turbines include one or more surfactants, one or more corrosion inhibiting dispersants, and one or more balance materials selected from a group consisting of water and solvents. The one or more surfactants and the one or more corrosion inhibiting dispersants combine to comprise from about 1 weight percent to about 20 weight percent, as actives, of the cleansing wash. | 2015-03-19 |
20150080283 | AMYLASE VARIANTS - The present invention relates to variants of a parent α-amylase, which parent α-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 7, respectively; or (ii) displays at least 80% homology with one or more of these amino acid sequences; and/or displays immunological cross-reactivity with an antibody raised against an α-amylase having one of these amino acid sequences; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding an α-amylase having one of these amino acid sequences; in which variant: | 2015-03-19 |
20150080284 | LAUNDRY CARE COMPOSITIONS CONTAINING DYES - Laundry care compositions comprising thiophene azo carboxylate fabric shading dyes and methods of treating a textile comprising such laundry care compositions. | 2015-03-19 |
20150080285 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents that do not require or require a reduced amount of scavenger materials. Such encapsulated benefit agents, compositions comprising such encapsulated benefit agents are processed such that no or lower levels of scavenger materials are required. | 2015-03-19 |
20150080286 | FABRIC SOFTENER ACTIVE COMPOSITION AND METHOD FOR MAKING IT - Reacting at least one tris-(2-hydroxyethyl)-amine fatty acid ester with dimethylsulfate at a molar ratio of dimethylsulfate to amine nitrogen of from 0.79 to 0.94 until the reaction mixture has a total amine number of from 7 to 20 mg KOH/g provides novel fabric softener active compositions with a low content of methanol, comprising from 65 to 98% by weight of tris-(2-hydroxyethyl)-methylammonium methylsulfate fatty acid esters and from 1 to 1500 ppm methanol. | 2015-03-19 |
20150080287 | METHOD FOR PREPARATION OF 2-(2,3-DIMETHYLPHENYL)-1-PROPANAL - The invention discloses a method for preparation of 2-(2,3-dimethylphenyl)-1-proponal from bromo 2,3-dimethyl-benzene and aceton, its use in perfumes and its use for the preparation of medetomidine. | 2015-03-19 |
20150080288 | NITRATION SHIELDING PEPTIDES AND METHODS OF USE THEREOF - Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1α, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1α, respectively are also provided. | 2015-03-19 |
20150080289 | PEPTIDES AND USES THEREOF - Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides. | 2015-03-19 |
20150080290 | COMPOSITIONS AND USES OF ANTIMICROBIAL MATERIALS WITH TISSUE-COMPATIBLE PROPERTIES - Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken. | 2015-03-19 |
20150080291 | SHORT ANTIMICROBIAL LIPOPEPTIDES - Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-microbial activity over the base tri-peptides, lysine-proline-valine and lysine-d-proline-tyrosine. The disclosed peptides have the general formula of C12-18 lipid-KXZ-NH | 2015-03-19 |
20150080292 | Cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) and methods of making and using the same - This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of | 2015-03-19 |
20150080293 | LECTINS AND USES THEREOF - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides antiviral and antimicrobial lectin compounds and methods of their use. | 2015-03-19 |
20150080294 | METHODS FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN - The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating catestatin in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject. | 2015-03-19 |
20150080295 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2015-03-19 |
20150080296 | Nutritive Fragments, Proteins and Methods - Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. | 2015-03-19 |
20150080297 | PEDIATRIC FIBER MIXTURE - The present invention relates to a liquid nutritional composition for paediatric patients comprising beta-galacto-oligosaccharides, fructan, non-digestible alpha-glucan and hemicellulose. | 2015-03-19 |
20150080298 | METHOD FOR TREATING HYPERGLYCEMIA - A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system. | 2015-03-19 |
20150080299 | CONCENTRATED PROTEIN PREPARATIONS OF BONE MORPHOGENETIC PROTEINS AND METHODS OF USE THEREOF - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 2015-03-19 |
20150080300 | GROWTH FACTOR CONCENTRATE AND THE USE THEREOF - Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma. | 2015-03-19 |
20150080301 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF - Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials. | 2015-03-19 |
20150080302 | NEUREGULIN ISOFORMS, NEUREGULIN POLYPEPTIDES AND USES THEREOF - The present invention relates to new therapeutic and diagnostic uses of soluable neuregulin-1 isoforms and polypeptides, particularly neurological disorders. | 2015-03-19 |
20150080303 | DEVICE HAVING OSTEOINDUCTIVE AND OSTEOCONDUCTIVE PROPERTIES - The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention. | 2015-03-19 |
20150080304 | TREATMENT AND PREVENTION OF RADIATION INJURY USING MFG-E8 - Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8). | 2015-03-19 |
20150080305 | APPLICATION OF INITIAL DOSES OF LHRH ANALOGUES AND MAINTENANCE DOSES OF LHRH ANTAGONISTS FOR THE TREATMENT OF HORMONE-DEPENDENT CANCERS AND CORRESPONDING PHARMACEUTICAL KITS - LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration. | 2015-03-19 |
20150080306 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 2015-03-19 |
20150080307 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 2015-03-19 |
20150080308 | Formulations and Uses of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 2015-03-19 |
20150080309 | Compounds Suitable for Treatment of Haemophilia - The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases. | 2015-03-19 |
20150080310 | BIOCOMPATIBLE COMPOSITION - A biocompatible composition which comprises crosslinkable serum albumin, crosslinkable serum protein and/or crosslinkable derivatives derived therefrom, and which is polymerizable to give a hydrogel-forming material, is used in a method for the prevention of pathological adhesions. | 2015-03-19 |
20150080311 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R) | 2015-03-19 |
20150080312 | HEXADEPSIPEPTIDE ANALOGUES AS ANTICANCER COMPOUNDS - This invention relates to an isolated, compound of Formula (1) | 2015-03-19 |
20150080313 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically. | 2015-03-19 |
20150080314 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 2015-03-19 |
20150080315 | SALL4 And Uses Thereof - The invention is directed to methods of treating a solid tumor which expresses SALL4 and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed methods of method of detecting an aggressive cancer in an individual in need thereof comprising detecting whether one or more cancer cells of the individual expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells, then an aggressive cancer is detected in the individual, and methods of method of detecting a poor prognosis of a patient with cancer in an individual in need thereof, comprising detecting whether one or more cancer cells of the patient expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells of the patient, then a poor prognosis is detected in the patient. | 2015-03-19 |
20150080316 | FUNCTIONALIZED THIENO-INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER - The invention relates to new functionalized thieno-indole derivatives of formula (I) or (II) which have cytotoxic activity and are useful in treating diseases such as cancer and cellular proliferation disorders. The invention also relates to the use of these functionalized thieno-indole derivatives in the preparation of conjugates. Formula (I) or (II) wherein R | 2015-03-19 |
20150080317 | TEMPLATE-FIXED PEPTIDOMIMETICS - The template-fixed B-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala- | 2015-03-19 |
20150080318 | Compositions for the Treatment or Prophylaxis of Viral Infections - A compound of the general formula (III): wherein X is O, S, NH or CH | 2015-03-19 |
20150080319 | Inhibition Of Tace Activity With Cyclic Peptides - A method is provided for inhibiting TACE activity in a human subject, through the administration of a θ-defensin, analog, or derivative. Such a θ-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The θ-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity. | 2015-03-19 |
20150080320 | MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS - The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer. | 2015-03-19 |
20150080321 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 2015-03-19 |
20150080322 | SUSTAINED-RELEASE COMPOSITION AND METHOD FOR PRODUCING THE SAME - Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same. | 2015-03-19 |
20150080323 | NUTRITIVE COMPOSITIONS AND METHODS OF USING SAME - The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from strict fluid management. | 2015-03-19 |
20150080324 | Aryl Derivatives And Uses Thereof - The present invention relates to antimalarial compounds and their use against protozoa of the genus | 2015-03-19 |
20150080325 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE - This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification. | 2015-03-19 |
20150080326 | PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed. | 2015-03-19 |
20150080327 | Targeted Osmotic Lysis of Cancer Cells - A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na | 2015-03-19 |
20150080328 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DISORDERS - The present invention relates to compounds and compositions and their application as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject. | 2015-03-19 |
20150080329 | PHARMACEUTICAL COMPOSITIONS COMPRISING DHA, EPA, AND/OR GLA AND AN ANTIBIOTIC AGENT AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DHA, EPA and/or GLA, used in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection. | 2015-03-19 |
20150080330 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 2015-03-19 |
20150080331 | GLUTAMINE & TREHALOSE COMPOSITIONS - Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed. | 2015-03-19 |
20150080332 | SULFATED POLYSACCHARIDE COMPOUND AND THE PREPARATION AND USE THEREOF - The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use. | 2015-03-19 |
20150080333 | HYALURONIC ACID PARTICLES AND THEIR USE IN BIOMEDICAL APPLICATIONS - Hyaluronic acid particles and their use in biomedical applications are provided. In one embodiment, an HA particle comprising a plurality of free polymer chains extending from a surface of the particle such that the polymer chains are capable of association with polymers or with polymer chains on a surface of other particles is provided. | 2015-03-19 |
20150080334 | MATERNAL SUPPLEMENT TO ENHANCE IMMUNE SYSTEM OF AN INFANT - There is provided compositions and methods for enhancing an immune system and/or preventing an immune system related disorder in a mammalian subject, the composition comprising a non-digestible oligosaccharide which is to be administered to a female who is breast-feeding the mammalian subject. | 2015-03-19 |
20150080335 | PROCESS FOR PRODUCING LOW ENDOTOXIN CHITOSAN - The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products. | 2015-03-19 |
20150080336 | ASSOCIATION OF BETA-GLUCANS AND ARABINOXYLANS - The present invention relates to an association of beta-glucans from a first cereal and arabinoxylans from a second cereal different from the first cereal, and their use to improve the microbiota balance in human gut. | 2015-03-19 |
20150080337 | N-CYCLOALKYL-N-[(TRISUBSTITUTEDSILYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES - The present invention relates to fungicidal N-cycloalkyl-N-[(trisubstitutedsilylphenyl)methylene]carboxamide derivatives and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2015-03-19 |
20150080338 | COSMETIC COMPOSITION COMPRISING A SILANE AND A LIPOPHILIC THICKENER - The present invention relates to a composition comprising at least one lipophilic thickener and at least one silane corresponding to formula (I) below and/or oligomers thereof: R | 2015-03-19 |
20150080339 | BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER - The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer. | 2015-03-19 |
20150080340 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES - Oligonucleotide analogues comprising boronic acid and/or boronic ester moieties are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects. | 2015-03-19 |
20150080341 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS - The inventive boronic acid analogs are potent inhibitors of Arginase I and II activity. These compounds are candidate therapeutics for treating a disease or disorder associated with an imbalance in the activity or concentration of cellular arginase I and arginase II enzymes. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the compositions for therapy. | 2015-03-19 |
20150080342 | BENZOXABOROLE COMPOUNDS AND USES THEREOF - Norvaline and/or other amino acids that are capable of being acylated onto tRNA | 2015-03-19 |
20150080343 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections - The present invention features compounds of formula (I): | 2015-03-19 |
20150080344 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS - There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus. | 2015-03-19 |
20150080345 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans. | 2015-03-19 |
20150080346 | MOISTURIZING COMPOSITION - The present invention relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least glyceryl caprylate, 1,3-propanediol and phytic acid or any of the salts thereof, said composition being free from perlite. | 2015-03-19 |
20150080347 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 2015-03-19 |
20150080348 | Compositions And Methods For Amelioration And Prevention Of Drug-Induced Toxicity - Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication. | 2015-03-19 |
20150080349 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS - The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups. | 2015-03-19 |
20150080350 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE - The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na | 2015-03-19 |
20150080351 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2015-03-19 |
20150080352 | AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE - The present invention describes a surprising effect of an aqueous polyurethane dispersion on the efficacy of active ingredients in the anti-acne treatment. The aqueous polyurethane dispersion was able to reduce irritation and substantially enhance efficacy of the salicylic acid and/or salicylic acid derivative in the topical anti-acne serum. | 2015-03-19 |
20150080353 | PHARMACEUTICAL COMPOSITIONS FOR THE DELIVERY OF SUBSTANTIALLY WATER-INSOLUBLE DRUGS - The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable. | 2015-03-19 |
20150080354 | MEDICAMENTS AND METHODS FOR TREATING CANCER - Medicaments and methods for treating cancer are disclosed. | 2015-03-19 |
20150080355 | Pharmaceutical Compositions Comprising Ebastine and Fluticasone - A pharmaceutical composition comprises at least one antihistamine, at least one corticosteroid, and at least one pharmaceutical excipient, wherein the at least one antihistamine comprises ebastine or its pharmaceutically acceptable salt, solvate, ester or physiologically functional derivative thereof, and wherein the at least one corticosteroid comprises fluticasone or its pharmaceutically acceptable ester thereof. | 2015-03-19 |
20150080356 | METHOD FOR IMPROVING THERAPY FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS - In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases. | 2015-03-19 |
20150080357 | ORGANIC COMPOUNDS - Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2015-03-19 |
20150080358 | Pharmaceutical Composition - The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration), to a process for preparing such a composition and to the use of such a composition for the treatment and/or prevention of respiratory, inflammatory or obstructive airway disease. | 2015-03-19 |
20150080359 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases. | 2015-03-19 |
20150080360 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 2015-03-19 |
20150080361 | VETERINARY COMPOSITIONS - The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration. | 2015-03-19 |
20150080362 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE - The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens. | 2015-03-19 |
20150080363 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE - The present invention relates to compounds defined by formula I: wherein the variables A | 2015-03-19 |
20150080364 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME - Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity. | 2015-03-19 |
20150080365 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT - This invention relates to certain heteroaryl compounds for use as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of helminth infections and the treatment of parasitosis caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds. | 2015-03-19 |
20150080366 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS - Compounds of Formula (I) wherein n, A, R | 2015-03-19 |
20150080367 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF - The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. | 2015-03-19 |
20150080368 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - The present invention relates to a compound of the formula I | 2015-03-19 |
20150080369 | NOVEL COMPOUNDS - The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ. | 2015-03-19 |
20150080370 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 2015-03-19 |
20150080371 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER - This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fJ[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases. | 2015-03-19 |
20150080372 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including melanoma, glioma, glioblastoma, pilocytic astrocytoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, bladder cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, kidney cancer, ovarian cancer, adrenocortical cancer, prostate cancer, gastrointestinal stromal tumors, medullary thyroid cancer, tumor angiogenesis, acute myeloid leukemia, chronic myelomonocytic leukemia, childhood acute lymphoblastic leukemia, plasma cell leukemia, and multiple myeloma. | 2015-03-19 |
20150080373 | NOVEL BICYCLIC ANTIBIOTICS - The antibacterial compound of formula I | 2015-03-19 |